Novartis Ag (NVS) Receivables - Net (2017 - 2025)
Novartis Ag (NVS) has disclosed Receivables - Net for 9 consecutive years, with $8.9 billion as the latest value for Q4 2025.
- Quarterly Receivables - Net rose 20.4% to $8.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.9 billion through Dec 2025, up 20.4% year-over-year, with the annual reading at $8.9 billion for FY2025, 20.4% up from the prior year.
- Receivables - Net hit $8.9 billion in Q4 2025 for Novartis Ag, up from $7.4 billion in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $8.9 billion in Q4 2025 to a low of $7.1 billion in Q4 2023.
- Historically, Receivables - Net has averaged $7.9 billion across 5 years, with a median of $8.0 billion in 2021.
- Biggest five-year swings in Receivables - Net: fell 11.89% in 2023 and later rose 20.4% in 2025.
- Year by year, Receivables - Net stood at $8.0 billion in 2021, then rose by 0.76% to $8.1 billion in 2022, then decreased by 11.89% to $7.1 billion in 2023, then grew by 4.45% to $7.4 billion in 2024, then grew by 20.4% to $8.9 billion in 2025.
- Business Quant data shows Receivables - Net for NVS at $8.9 billion in Q4 2025, $7.4 billion in Q4 2024, and $7.1 billion in Q4 2023.